16 June 2017Americas

Johnson & Johnson reveals obesity and 3D printing collaborations

Johnson & Johnson (J&J) Innovation, the division that focuses on forming collaborations between entrepreneurs and J&J’s healthcare businesses, has announced a series of new collaborations.

Janssen Pharmaceuticals, a subsidiary of J&J, has formed a multi-project collaboration with the University of California San Diego School of Medicine.

The collaboration will identify pathways and mechanisms driving disease progression, as well as clinically useful biomarkers, therapeutic targets and gastric bypass approaches that could yield improved treatments for obesity and related conditions.

Johnson & Johnson Services, another division of J&J, has executed a research collaboration with Inkbit Corporation, a 3D printing startup recently spun out of the Massachusetts Institute of Technology.

“3D printing holds the potential to create customised health solutions that can mean increased satisfaction and better outcomes for patients,” said J&J Innovation in a  statement released yesterday, June 15.

Janssen Biotech has formed a multi-year collaboration and prenegotiated option-to-license agreement with Monash University, Australia, to discover and develop biologic next-generation therapeutics to treat, prevent and intercept rheumatoid arthritis.

According to J&J, rheumatoid arthritis affects more than 1.3 million adults in the US and nearly 1% of the world’s population.

Other partnerships will focus on advancing improvements for contact lenses, improving manufacturing efficiencies, and developing a platform that learns how human microbiome communities interact with the host through analysis of genetic, functional and metabolic data.

Additionally, through an effort to advance global public health, Janssen Pharmaceutical Companies is sharing its molecular compound libraries with collaborators developing treatments for diseases of the developing world.

Paul Stoffels, chief scientific officer of J&J, said: "Fulfilling the unmet needs facing patients today requires continued investment in the ideas that could become the healthcare solutions that improve and extend patients’ lives in the future.”

Today’s stories:

Section 101 raises fundamental question: 3M

Panellists tackle patent concerns after Brexit

FBI agent and lawyers provide trade secret tips

Industry at a crossroads over section 101

Pfizer and Takeda help to tackle Africa cancer crisis

Academic patents gave $1.3tn to US output

David Cameron talks Brexit, Trump and genomes

Teva must pay $235m to GSK

Hospira sued for infringing allergic injection patent

Google’s parent company invests $300m in biotech

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
14 September 2018   Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.

More on this story

Europe
14 September 2018   Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.

More on this story

Europe
14 September 2018   Johnson & Johnson announced this week that its subsidiary J&J Medical has acquired Emerging Implant Technologies (EIT) for an undisclosed amount.